Anti-PD1 Monoclonal Antibody

Identifier: CI-DRUG-00000068
Entity page: /drug/anti-pd1-monoclonal-antibody ↗
Edges: 66

Neighbours: 15 cancers2 variants10 trials
Drawn: 27 of 27 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Anti-PD1 Monoclonal Antibody predicts response to …PREDICTS_RESPONSE_TO2 of 2
← predicts response to	PRKDC Mutationother	sensitivity	B	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
← predicts response to	EGFR Exon 19 Deletiondeletion	resistance	B

Anti-PD1 Monoclonal Antibody investigated for …INVESTIGATED_FOR1 of 1
→ investigated for	Lung Non-Small Cell Carcinomasubtype 2 source records aggregated	supports	B	Lung Non-Small Cell Carcinoma	2	Curated	civic	graph →

Anti-PD1 Monoclonal Antibody investigated for …INVESTIGATED_FOR1 of 1

→ investigated for

Lung Non-Small Cell Carcinomasubtype

2 source records aggregated

supports

Lung Non-Small Cell Carcinoma

Curated

Anti-PD1 Monoclonal Antibody investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 28show all (up to 200)
→ investigated in trials for	Solid Neoplasm 6 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Hepatocellular Carcinoma 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hepatocellular Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Nasal Type Extranodal NK/T-Cell Lymphoma 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Nasal Type Extranodal NK/T-Cell Lymphoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Gastric Adenocarcinoma 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Gastric Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Colorectal Neoplasm 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colorectal Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Pancreatic Neoplasm 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Pancreatic Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Melanoma 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Melanoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Adenocarcinoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Biliary Tract Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Biliary Tract Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Colorectal Adenocarcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Colorectal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Esophageal Squamous Cell Carcinoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Esophageal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Extranodal NK-/T-Cell Lymphoma, Nasal Type 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Extranodal NK-/T-Cell Lymphoma, Nasal Type	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Gastric Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Gastric Neoplasm	1	Observed	clinicaltrials	graph →

Anti-PD1 Monoclonal Antibody studied in …STUDIED_INderived10 of 35show all (up to 200)
→ studied in	NCT06470971Phase 2 · recruiting Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial · 35 trials list this drug (19 active)	—	—	Hematopoietic and Lymphatic System Neoplasm,Malignant Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07830355Phase 2 · not yet recruiting Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph Nodes · 35 trials list this drug (19 active)	—	—	Esophageal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05254899Phase 2 · completed A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102) · 35 trials list this drug (19 active)	—	—	Nasal Type Extranodal NK/T-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06425926Phase 1/Phase 2 · recruiting Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors · 35 trials list this drug (19 active)	—	—	Solid Neoplasm,Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05774275Phase 1/Phase 2 · recruiting The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma · 35 trials list this drug (19 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT07365592Phase 1/Phase 2 · recruiting Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC · 35 trials list this drug (19 active)	—	—	Malignant Colorectal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05182957Phase 2 · recruiting Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma · 35 trials list this drug (19 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT07288034Phase 2 · recruiting Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial · 35 trials list this drug (19 active)	—	—	Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07090148Phase 1 · recruiting Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC · 35 trials list this drug (19 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03983057Phase 2 · completed Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer · 35 trials list this drug (19 active)	—	—	Malignant Pancreatic Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths